Cited 0 times in
Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.date.accessioned | 2023-06-02T00:51:54Z | - |
dc.date.available | 2023-06-02T00:51:54Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194481 | - |
dc.description.abstract | Introduction: To compare the efficacy of abatacept and tumor necrosis factor inhibitor (TNFi) in patients with anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) and identify those who benefit most from abatacept over TNFi. Methods: This observational study identified RA patients who were ACPA-positive and initiated abatacept or TNFi from the Korean College of Rheumatology Biologics and Targeted therapy registry. Propensity score (PS) matching was performed to balance baseline confounding in abatacept- or TNFi-treated patients. The major endpoints were changes in Clinical Disease Activity Index (CDAI) and achievement of CDAI remission/low disease activity after 1 year of treatment. Subgroup analysis was mainly performed stratified by prior biologics use. Results: A total of 291 PS-matched, ACPA-positive RA patients who initiated abatacept (n = 97) and TNFi (n = 194) were included. From baseline CDAI scores of 26.52 in the abatacept group and 26.38 in the TNFi group, the mean changes after 1 year were - 16.78 and - 13.61, respectively (difference - 3.17, p = 0.020). The proportion of patients achieving CDAI remission/low disease activity was 68.0% with abatacept and 52.6% with TNFi (p = 0.013). In the subgroup analysis, patients that were biologics-naïve had better improvement in CDAI after treatment with abatacept than TNFi (difference - 3.35, p = 0.021). Conclusions: This real-world study suggests that abatacept may have better clinical response compared to TNFi in patients with established ACPA-positive RA, especially in those that were biologics-naïve. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | RHEUMATOLOGY AND THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Min Jung Kim | - |
dc.contributor.googleauthor | Sun-Kyung Lee | - |
dc.contributor.googleauthor | Sohee Oh | - |
dc.contributor.googleauthor | Hyoun-Ah Kim | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Shin-Seok Lee | - |
dc.contributor.googleauthor | Kichul Shin | - |
dc.identifier.doi | 10.1007/s40744-022-00467-4 | - |
dc.contributor.localId | A01579 | - |
dc.relation.journalcode | J04446 | - |
dc.identifier.pmid | 35716235 | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | 박용범 | - |
dc.citation.volume | 9 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1143 | - |
dc.citation.endPage | 1155 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY AND THERAPY, Vol.9(4) : 1143-1155, 2022-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.